SANTA MONICA, Calif. / Jan 31, 2023 / Business Wire / GoodRx Holdings Inc. (Nasdaq: GDRX), a leading digital healthcare platform, today announced it will release its fourth quarter and full year 2022 financial results after U.S. markets close on Tuesday, February 28, 2023. GoodRx management will also hold a conference call and webcast that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company’s business outlook.
To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company’s investor relations website at https://investors.goodrx.com, where accompanying materials will be posted prior to the conference call.
Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s investor relations website at https://investors.goodrx.com for at least 30 days.
About GoodRx
GoodRx is a leading digital healthcare platform that makes healthcare affordable and convenient for all Americans. We offer consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. Since 2011, we have helped consumers save over $45 billion and are one of the most downloaded medical apps over the past decade.
Last Trade: | US$4.75 |
Daily Change: | -0.08 -1.66 |
Daily Volume: | 1,114,088 |
Market Cap: | US$476.420M |
May 07, 2025 February 27, 2025 January 22, 2025 December 16, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load